Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfactionExploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithmsData from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gest